AZN logo

AZN

AstraZeneca PLC

$189.75
-$2.55(-1.33%)
50
Overall
50
Value
36
Tech
65
Quality
How is this score calculated?
Market Cap
$314.14B
Volume
2.39M
52W Range
$132.32 - $212.71
Target Price
$206.99

Company Overview

Mkt Cap$314.14BPrice$189.75
Volume2.39MChange-1.33%
P/E Ratio30.7Open$189.15
Revenue$58.7BPrev Close$192.30
Net Income$10.2B52W Range$132.32 - $212.71
Div Yield5.30%Target$206.99
Overall50Value50
Quality65Technical36

No chart data available

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector: Healthcare
Industry: Drug Manufacturers - Major

Latest News

AstraZeneca Advances New Imaging Tool in Targeted Lung Cancer Trial

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca Launches Early Scan Study in Targeted Lung Cancer The ph...

TipRanks Clinical-Trials-Auto-Generated Newsdeska day ago

Osimertinib Cements Lead in EGFR Lung Cancer as AstraZeneca Updates Key Phase 3 Trial

TipRanks Clinical-Trials-Auto-Generated Newsdesk3 days ago

AstraZeneca’s Baxdrostat Trial Completion Puts Resistant Hypertension Opportunity in Focus

TipRanks Clinical-Trials-Auto-Generated Newsdesk3 days ago

AstraZeneca Expands Real‑World Evidence for Acalabrutinib in CLL

TipRanks Clinical-Trials-Auto-Generated Newsdesk6 days ago

AstraZeneca’s Danicopan Korea Study: Real-World Data That Could Shape AZN’s Rare Disease Edge

TipRanks Clinical-Trials-Auto-Generated Newsdesk6 days ago
ABCD
1SymbolPriceChangeVol
2AZN$189.75-1.3%2.39M
3
4
5
6

Get AstraZeneca PLC Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.